Skip to main content

Table 1 Deriving the PNH risk-factor score

From: Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Clinical indicator Specific level of clinical indicator Assigned value
Observed LDH category LDH < 1.5×ULN 2
  LDH 1.5–< 3×ULN 4
  LDH ≥ 3xULN 6
Observed pRBC stratum 0 unit pRBC NA
  1–14 units pRBC NA
  > 14 units pRBC NA
Immuno-suppressant treatment No 1
  Yes 2
Aplastic anemia No 1
  Yes 2
Myelodysplastic syndrome No 1
  Yes 2
Bone marrow disorder No 1
  Yes 2
Summary score creation   
Sum all assigned values Sum assigned values for observed LDH, Immuno-suppressant treatment, aplastic anemia, myelodysplastic syndrome, and bone marrow disorder  
Create PNH risk-factor group   
  Lower 6–8
  Higher 9–12
  1. NA: Since pRBC was not used in the 302 trial, it was not included among the clinical indicators used for the risk-factor score